Evidence map›Paper›PMID 40687685›Full record

ReviewInternational journal of physiology, pathophysiology and pharmacology2025

Risk of fracture with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: an updated meta-analysis of randomized controlled trials.

Mahdieh Khoshzaban Banisi, Ehsan Emami, Mahdiyeh Nozad Varjovi, Alireza Shayesteh Kia, Mahtab Rasaiyan, Shayan Agha Amini Fashami, Niloofar Shirazi, Elahe Ahsan, Niloofar Deravi, Mahdyieh Naziri and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of physiology, pathophysiology and pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Association between SGLT2 inhibitor use and the risk of vertebral augmentation after initial osteoporotic vertebral fracture in patients with type 2 diabetes.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mahdieh Khoshzaban BanisiStudent Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences Tehran, Iran.
Ehsan EmamiStudents Research Committee, School of Pharmacy, Tehran University of Medical Science Tehran, Iran.
Mahdiyeh Nozad VarjoviStudent Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences Tabriz, Iran.
Alireza Shayesteh KiaStudent Research Committee, School of Medicine, Islamic Azad University, Tehran Medical Branch Sciences Tehran, Iran.
Mahtab RasaiyanStudent Research Committee, School of Pharmacy, Hamadan University of Medical Sciences Hamadan, Iran.
Shayan Agha Amini FashamiStudent Research Committee, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.
Niloofar ShiraziWestern University of Health Sciences 309 E 2nd St, Pomona, CA 91766, USA.
Elahe AhsanSchool of Medicine, Shahid Beheshti University of Medical Sciences Tehran, Iran.
Niloofar DeraviStudent Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences Tehran, Iran.
Mahdyieh NaziriStudent Research Committee, School of Medicine, Iran University of Medical Sciences Tehran, Iran.
Roza ZareiStudents Research Committee, School of Pharmacy, Islamic Azad University Pharmaceutical Sciences Branch Tehran, Iran.
Niloufar ShabaniSchool of Medicine, Shahid Beheshti University of Medical Sciences Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (T2DM) increases the risk of fractures. This meta-analysis compared the effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i) on fracture risk in patients with T2DM.

methodA systematic search of PubMed, Web of Science, Embase, and Google Scholar was conducted up to August 6, 2023. Seven cohort studies (n = 1,199,267 participants at baseline; n = 357,119 after propensity matching) comparing SGLT-2i use with DPP-4i use and reporting fracture outcomes were included. Data were extracted and analyzed using a random-effects model. Subgroup analyses were performed by age (<70 and ≥70 years) and sex.

resultsIn general, SGLT-2i therapy was linked to reduced fracture risk when compared to DPP-4i (OR: 0.89, 95% CI: 0.81-0.98). Heterogeneity was high (I

conclusionThis meta-analysis indicates SGLT-2i therapy could be linked with reduced overall fracture risk in comparison to DPP-4i in the general population of T2DM. The benefit was not seen in subgroup analysis based on age and sex. Additional research, ideally with increased cases within subgroups, is required to determine the impact of these drugs on fracture risk in patient subgroups.

Indexed as

cohort studiesdipeptidyl peptidase-4 inhibitorselderly patientsfracture risksodium-glucose cotransporter-2 inhibitorsType 2 diabetes mellitus

Identifiers

PMID40687685
PMCPMC12267119

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.